X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor with a unique chemical structure developed to inhibit the growth of cancer cells. FDA has approved its use in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
The sNDA is based on positive results from pivotal Phase III ARASENS trial demonstrating a statistically significant improvement in overall survival for Nubeqa (darolutamide) plus androgen deprivation therapy and docetaxel in men with mHSPC compared to ADT plus docetaxel.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor with a unique chemical structure developed to inhibit the growth of cancer cells. FDA has approved its use in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
The ARASENS trial, Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy significantly increased overall survival for patients with metastatic hormone-sensitive prostate cancer.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2021
Iran Expo
Not Confirmed
Contact Supplier
Details:
ABVC would grant OncoX an exclusive global rights to develop and commercialize its oncology/hematology pipeline, including ABV-1519 for triple negative breast cancer, ABV-1501 for NSCLC, ABV-1702 for myelodysplastic syndrome and ABV-1703 for pancreatic cancer.
Lead Product(s): ABV-1519,Docetaxel
Therapeutic Area: Oncology Product Name: IND 129575
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OncoX BioPharma
Deal Size: $105.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement April 10, 2024
Details:
Taxedol (docetaxel) is a USFDA approved Tubulin depolymerization inhibitor. It is now approved in Israel for the treatment of breast, prostate, head, neck and non-small cell lung cancer.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Taxedol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2023
Details:
Under the agreement, Bristol licensed BMS-986442 (AGEN1777), a dual TIGIT and CD96 antagonist with an enhanced Fc region to improve tumor-reactive T cell responses, from Agenus and currently dosed first patient in the phase 2 of the ongoing clinical trial.
Lead Product(s): AGEN1777,Docetaxel,Nivolumab
Therapeutic Area: Oncology Product Name: BMS-986442
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $1,560.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement December 11, 2023
Details:
ADI-PEG 20 (pegargiminase) is an Arginine Degrader Enzyme drug candidate, which is currently being evaluating clinical trial studies with patients for the treatment of Leiomyosarcoma.
Lead Product(s): Pegargiminase,Gemcitabine,Docetaxel
Therapeutic Area: Oncology Product Name: ADI-PEG 20
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
PDS0301 is a novel investigational tumor-targeting antibody drug conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency and longevity of T cells and natural killer (NK) cells in the tumor microenvironment.
Lead Product(s): PDS0301,Docetaxel
Therapeutic Area: Oncology Product Name: PDS0301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Ditaxel (docetaxel) is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions, by binding to free tubulin and promotes its assembly into stable microtubules while inhibiting their disassembly.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Docetaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
IDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A) and evaluating Phase 1/2 clinical trial in patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.
Lead Product(s): IDE397,Docetaxel
Therapeutic Area: Oncology Product Name: IDE397
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions, by binding to free tubulin and promotes its assembly into stable microtubules while inhibiting their disassembly.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Docetaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Under the collaboration BioNTech will receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392 (gotistobart), as monotherapy or combination therapy in various cancer indications.
Lead Product(s): Gotistobart,Docetaxel
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Collaboration March 20, 2023
Details:
ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, designed to be an effective anti-cancer therapeutic which can be taken at home and which eliminates or reduces serious, treatment-limiting side effects.
Lead Product(s): Docetaxel,Ritonavir
Therapeutic Area: Oncology Product Name: ModraDoc006/r
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
BPI-2358 (plinabulin) triggers the release of the immune defense protein, GEF-H1, which leads to a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells.
Lead Product(s): Plinabulin,Docetaxel,Pembrolizumab
Therapeutic Area: Oncology Product Name: BPI-2358
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions, by binding to free tubulin and promotes its assembly into stable microtubules while inhibiting their disassembly.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Docetaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions, by binding to free tubulin and promotes its assembly into stable microtubules while inhibiting their disassembly.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Docetaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
It has received marketing authorisation for its generic alternative cancer drugs carboplatin from Uzbekistan and docetaxel and irinotecan from Palestine.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Docetaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Nubeqa™ (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or NovoTTF-200T (Docetaxel) versus immune checkpoint inhibitors or docetaxel alone.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: NovoTTF-200T
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
BPI-2358 (Plinabulin), BeyondSpring’s lead asset, is a selective immunomodulating microtubule-binding agent, which is a potent antigen presenting cell (APC) inducer that is being developed as an anticancer agent.
Lead Product(s): Plinabulin,Docetaxel
Therapeutic Area: Hematology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Polytaxel is loaded with docetaxel as its active pharmaceutical ingredient, which is known as one of the major chemotherapy drugs. This chemotherapy is a patient-centered treatment that focuses on controlling toxicity of anticancer drug.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Polytaxel
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2022
Details:
IDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), in patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.
Lead Product(s): IDE397,Docetaxel
Therapeutic Area: Oncology Product Name: IDE397
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
Darolutamide (nubeqa) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
LSAM-DTX (docetaxel) is retained in the tumor for continuous drug release after intratumoral injection in a range of solid tumor preclinical models and in combination with an immune checkpoint inhibitor demonstrated synergy in a preclinical metastatic breast cancer model.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: LSAM-DTX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Nubeqa (darolutamide), is an oral androgen receptor inhibitor with distinct chemical structure that binds to receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
Approval is based on results trial that demonstrated statistically significant increase in overall survival (OS), trial’s primary endpoint, with reduction in risk of death by 32% for those treated with NUBEQA (darolutamide) plus ADT and docetaxel compared to ADT and docetaxel.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
The ARASENS trial demonstrated that Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% compared to ADT plus docetaxel.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA (pembrolizumab) in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of OS and radiographic progression-free survival for treatment of patients with mCRPC.
Lead Product(s): Pembrolizumab,Docetaxel,Prednisone
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
In this Phase 1/2 clinical trial, NanoDoce (Docetaxel/LSAM-DTX) showed promising signs of preventing disease progression and interesting immunogenic effects with minimal adverse events.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: NanoDoce
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
IDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), in patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.
Lead Product(s): IDE397,Docetaxel
Therapeutic Area: Oncology Product Name: IDE397
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
The preclinical study of metastatic prostate cancer combining POL6326 (balixafortide) and docetaxel (5 mg/kg once weekly) assessed tumor burden and tumor-induced bone degradation. Overall, results showed superior synergistic efficacy compared to either drug alone.
Lead Product(s): Balixafortide,Docetaxel
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Data from Phase III ARASENS trial in patients with mHSPC, showed that Nubeqa (darolutamide) plus ADT and docetaxel provides consistently favorable OS benefits across patient subgroups with various types of metastatic disease, compared to placebo plus ADT and docetaxel.
Lead Product(s): Darolutamide,Androgen Deprivation Therapy,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2022
Details:
Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4.
Lead Product(s): Naptumomab Estafenatox,Docetaxel,Obinutuzumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Translational Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Reduction in local tumor recurrence in murine R2 resection model comparing locally administered docetaxel-releasing product, OncoPLEX, versus systemic docetaxel, demonstrated that locally administered OncoPLEX potentially decreases likelihood of tumor recurrence.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, a boosting agent which enhances bioavailability. In a total of 101 patients enrolled, ModraDoc006/r demonstrated a similar efficacy and an improved tolerability profile.
Lead Product(s): Docetaxel,Ritonavir
Therapeutic Area: Oncology Product Name: ModraDoc006/r
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
No DLTs were observed at DKN-01 300mg or 600mg dose levels as monotherapy or in combination with docetaxel, and no treatment-related adverse events occurred in either cohort.
Lead Product(s): DKN-01,Docetaxel
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
ModraDoc006/r (docetaxel) is a proprietary boosted taxane therapy based on docetaxel, an intravenously administered therapy, that is very broadly used in a variety of tumor types.
Lead Product(s): Docetaxel,Ritonavir
Therapeutic Area: Oncology Product Name: ModraDoc006/r
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Submission based on data ARASENS trial, showing that use of darolutamide plus androgen deprivation therapy and docetaxel led to a statistically significant improvement in overall survival compared to ADT plus docetaxel.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
TTX-030, a first-in-class, anti-CD39 antibody, inhibits the activity of CD39, an enzyme that converts ATP to AMP, the initial steps in the generation of adenosine in the tumor microenvironment.
Lead Product(s): Ttx-030,Docetaxel,Budigalimab
Therapeutic Area: Oncology Product Name: TTX-030
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.
Lead Product(s): Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Troika
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
The submissions are supported by positive results from the Phase III ARASENS trial, showing a statistically significant improvement in overall survival (OS) for Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) and docetaxel in men with mHSPC.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Cadonilimab, a bi-specific antibody with dual blockade of both PD-1 and CTLA-4 in combination with Docetaxel, reduce risk of delayed efficacy and pseudoprogression and may benefit patients with advanced NSCLC following PD-1/L1 inhibitor and platinum-based doublet chemotherapy.
Lead Product(s): Cadonilimab,Docetaxel
Therapeutic Area: Oncology Product Name: AK104
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
